NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
Clinical Trials
20 trialsNCT03493152 2025-05-28
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
The University of Texas Health Science Center at San Antonio
No longer available
NCT03114527 2025-04-04
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT03245151 2023-08-30
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Phase 1/2 Completed
NCT00387400 2023-08-04
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT01062399 2022-06-09
RTOG 0913
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT00553150 2020-02-13
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01804374 2015-06-17
SERIO
Italian Sarcoma Group
Phase 2 Completed
NCT00187174 2015-03-04
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01281865 2014-10-08
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01048723 2013-12-16
Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00927966 2013-11-14
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01216826 2013-08-07
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
Hospital Santa Marcelina
Phase 2 Unknown
NCT00107237 2013-06-12
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Novartis
Phase 1/2 Completed
NCT01830153 2013-04-12
RAD001 in Advanced Sarcoma
Asan Medical Center
Phase 2 Completed
NCT01216839 2013-03-26
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Hospital Santa Marcelina
Phase 2 Unknown
NCT00613132 2013-02-20
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Phase 1 Completed
NCT01412515 2012-01-02
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
Institut National de la Santé Et de la Recherche Médicale, France
Phase 2 Terminated